IGM Biosciences, Inc. / Fundamentals
Income statement
- Net revenue
€124.45M - Cost of goods sold
€2.40M - Gross profit
€122.06M - SG&A expenses
€41.83M - R&D expenses
€87.36M - EBITDA
-€26.85M - D&A
€6.33M - EBIT
-€23.90M - Interest expenses
€0.00 - EBT
-€45.80M - Tax expenses
€0.00 - Net income
-€45.80M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€128.94M - Changes in working capital
-€2.53M - Operating cash flow
-€134.29M - Capex
€1.88M - Other investing cash flow
€2.33M - Net investing cash flow
€101.47M - Total cash dividends paid
€0.00 - Issuance of common stock
-€719.86K - Debt repayment
€0.00 - Other financing cash flow
€1.41M - Net financing cash flow
€1.41M - Foreign exchange effects
€0.00 - Net change in cash
-€31.41M - Cash at end of period
€26.30M - Free cash flow
-€132.41M
Balance sheet
- Cash and cash equivalents
€26.30M - Cash and short-term investments
€89.49M - Total receivables
€429.00K - Inventory
€0.00 - Other current assets
€1.87M - Total current assets
€91.80M - Property, plant & equipment
€0.00 - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€0.00 - Total assets
€91.80M - Accounts payable
€2.06M - Short-term debt
€0.00 - Other current liabilities
€3.14M - Total current liabilities
€5.20M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€0.00 - Total liabilities
€5.20M - Common stock
€515.66K - Retained earnings
-€834.27M - Other equity
€6.86K - Total equity
€86.60M - Total liabilities and shareholders' equity
€91.80M
Company information
- Market capitalization
€55.38M - Employees
149 - Enterprise Value
€83.42M
Company ratios
- Gross margin
-
98.1% Much better than peer group: -645.8% - EBITDA margin
-
-21.6% Much better than peer group: -6,783.0% - EBIT margin
-
-19.2% Much better than peer group: -7,360.7% - EBT margin
-
-36.8% Much better than peer group: -7,179.9% - Net margin
-
-36.8% Much better than peer group: -7,137.3% - ROE
-
-52.9% Much worse than peer group: -6.7% - ROA
-
-49.9% Even with peer group: -45.4% - Asset turnover
-
135.6% Much better than peer group: 4.3% - FCF margin
-
-109.4% Much better than peer group: -6,072.4% - FCF yield
-245.9% - Efficiency ratio
121.6% - Net sales per employee
-
€835.26K - Net income per employee
-
-€307.41K